Januvia (sitagliptin) is a prescription medication used to lower blood sugar in adults with type 2 diabetes. It belongs to a class of drugs called DPP-4 inhibitors and is prescribed alongside diet and exercise, either on its own or combined with other diabetes medications. It is not approved for type 1 diabetes.
How Januvia Works
Your gut naturally releases two hormones after you eat, commonly called incretin hormones. These hormones signal your pancreas to produce more insulin and tell your liver to ease up on releasing stored sugar. The problem is that your body breaks down these hormones within minutes, cutting their effects short.
Januvia blocks the enzyme responsible for that breakdown. By keeping incretin hormones active longer, it helps your pancreas release more insulin when your blood sugar rises after a meal. It also reduces the amount of sugar your liver dumps into your bloodstream by suppressing glucagon, the hormone that triggers that release. Importantly, this process is glucose-dependent, meaning it ramps up when blood sugar is high and dials back when it’s normal. That built-in safety mechanism is a key reason Januvia carries a low risk of causing blood sugar to drop too low.
How Effective Januvia Is at Lowering Blood Sugar
Januvia lowers A1C (a measure of average blood sugar over about three months), but it produces more modest reductions than several other diabetes drug classes. The large GRADE trial, which compared four medications added to metformin in people with type 2 diabetes, found that at five years sitagliptin was the least effective of the four at achieving and maintaining an A1C below 7%. Insulin glargine and the GLP-1 receptor agonist liraglutide were modestly more effective.
The American Diabetes Association’s 2025 guidelines note that DPP-4 inhibitors like Januvia produce the smallest A1C reductions among the major diabetes drug classes. Metformin alone is also more effective at lowering A1C and weight. That doesn’t mean Januvia has no role, but it’s typically chosen when other options aren’t suitable or when its specific advantages, like a favorable side effect profile, matter more for a given patient.
Weight and Hypoglycemia Profile
Two concerns that come up with many diabetes medications are weight gain and hypoglycemia (dangerously low blood sugar). Januvia performs well on both counts. In a year-long comparison against glipizide (a common sulfonylurea), patients taking Januvia lost an average of 1.5 kg while those on glipizide gained 1.1 kg, a difference of about 5.5 pounds. The glipizide group also experienced more than 10 times as many episodes of hypoglycemia.
This combination of being weight-neutral and carrying a low hypoglycemia risk makes Januvia a reasonable choice for people who are particularly vulnerable to blood sugar crashes, such as older adults or those with irregular eating patterns.
Common Side Effects
Most people tolerate Januvia well. In clinical trials, the side effects reported more often with Januvia than with a placebo were upper respiratory tract infections, nasopharyngitis (the common cold), and headache. These occurred in 5% or more of patients. Many people experience no noticeable side effects at all.
Serious Risks to Be Aware Of
Pancreatitis is the most important safety concern. Post-marketing reports have documented cases of acute pancreatitis in people taking Januvia, including rare but severe forms. Symptoms to watch for include sudden, intense abdominal pain that may radiate to your back, often accompanied by nausea and vomiting. If you develop these symptoms, the medication should be stopped immediately.
Severe joint pain is another reported issue with DPP-4 inhibitors as a class. The onset can be unpredictable, appearing anywhere from one day to years after starting the medication. In reported cases, the pain resolved after stopping the drug but sometimes returned when the same or a similar medication was restarted.
Where Januvia Fits Among Diabetes Medications
For most people with type 2 diabetes, metformin remains the usual starting medication. When metformin alone isn’t enough, the choice of what to add depends on several factors: whether you have heart disease or kidney disease, your weight management goals, how much additional blood sugar lowering you need, and cost. Newer drug classes like GLP-1 receptor agonists (such as semaglutide and liraglutide) and dual GIP/GLP-1 receptor agonists (such as tirzepatide) offer stronger A1C reductions and significant weight loss benefits, which has pushed them higher in treatment guidelines.
Januvia occupies a more limited niche than it once did. It tends to be considered when GLP-1 receptor agonists aren’t tolerated, aren’t accessible, or when a simple oral tablet with minimal side effects is the priority. One important note: Januvia should not be taken alongside a GLP-1 receptor agonist or a dual GIP/GLP-1 receptor agonist, because combining them doesn’t improve blood sugar control beyond what the GLP-1 drug achieves on its own. They work on overlapping pathways, so doubling up adds cost without benefit.
Januvia is available as a once-daily tablet, which many people find convenient. It doesn’t require dose titration the way insulin does, and it doesn’t need to be injected. For patients who value simplicity and tolerability and whose blood sugar is only modestly above target, it can still be a practical option.